AbbVie Inc. with ticker code (ABBV) have now 26 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $225.00 and $170.00 suggesting an average analyst share price target price of $201.94. (at the time of writing). Now with the previous closing price of $189.65 and the analysts are correct then there would likely be a percentage uptick in value of 6.5%. It’s also worth noting that there is a 50 day moving average of $193.97 while the 200 day moving average is $177.05. The company has a market cap of 331.86B. Currently the stock stands at: $187.85 USD
The potential market cap would be $353,367,271,390 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 62.83, revenue per share of $31.10 and a 7.94% return on assets.
AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.
